U.S. FDA approves Gilead’s hepatitis C drug for expanded use

A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring(Reuters) – Drugmaker Gilead Sciences Inc said on Thursday the U.S. Food and Drug Administration had approved the expanded use of its blockbuster hepatitis C drug, Harvoni. The drug can now be used to treat patients with subtypes of chronic hepatitis C virus (HCV) and patients who are co-infected with Human Immunodeficiency Virus (HIV), Gilead said in a statement. Results from the study showed that about 93 percent of the patients with subtypes of the virus and 96 percent of patients co-infected with HIV showed a sustained response to the virus within 12 weeks of treatment.



Sexual Health News Headlines – Yahoo! News